Drug intelligence / Profile preview

ENV-6946

Development stage: Preclinical
Lead developer: Enveda Biosciences
Modality: Small Molecules
Administration: Oral

Overview

ENV-6946 is a nature-inspired small-molecule drug candidate being developed by Enveda Biosciences for the treatment of inflammatory bowel disease (IBD). Discovered using Enveda's AI-powered metabolomics platform, which identifies novel therapeutic compounds from natural sources, ENV-6946 is designed to address the underlying inflammatory processes in the gastrointestinal tract. The drug is intended for oral administration. As of early 2025, the program is in preclinical development and is expected to advance into clinical trials later in the year, supported by significant venture financing including a Series D round led by Premji Invest and strategic investment from Sanofi.

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TL1A (TNF-like cytokine 1A)

Beyond the preview

Go deeper on ENV-6946.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENV-6946.

Explore the full profile